SEC Form 4 · accession 0001209191-18-039558
Eloxx Pharmaceuticals, Inc. · ELOX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregory C. Williams
Officer — Chief Operating Officer
Period of report
Jun 25, 2018
Accepted (ET)
Jun 26, 2018 · 8:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001035354
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $18.84 | Jun 25, 2018 | A | 300,000 | A | — | Jun 25, 2028 | Common Stock | 300,000 | 300,000 | D |
Explanation of responses
- F1One third (1/3) of the shares underlying the option shall vest on June 25, 2019 (the "Cliff Vesting Date"), the remainder of the grant shall vest in equal installments on each quarterly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.